Small and emerging biopharma’s often are challenged to identify a CDMO partner that can truly grow with them. An organization may kick off drug development with one indication and light production volumes in mind, but as indications are added or demand outstrips their partner’s capacity, the biopharma must add more partners or transfer to a larger CDMO. Ideally, such organizations can depend on one CDMO partner, whether their therapy remains limited in its indication and production scope or expands exponentially. This presentation demonstrates Cambrex’s capabilities and how they can support the Cell & Gene Therapy players in the market.
To view the entire library of presentations from the Cell & Gene Outsourced Pharma Capacity Update, click here